KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Shares Outstanding (Diluted Average): 2009-2025

Historic Shares Outstanding (Diluted Average) for Arbutus Biopharma (ABUS) over the last 10 years, with Sep 2025 value amounting to $191.8 million.

  • Arbutus Biopharma's Shares Outstanding (Diluted Average) rose 1.47% to $191.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.8 million, marking a year-over-year increase of 1.47%. This contributed to the annual value of $185.6 million for FY2024, which is 11.84% up from last year.
  • Arbutus Biopharma's Shares Outstanding (Diluted Average) amounted to $191.8 million in Q3 2025, which was down 0.32% from $192.4 million recorded in Q2 2025.
  • Arbutus Biopharma's Shares Outstanding (Diluted Average)'s 5-year high stood at $192.4 million during Q2 2025, with a 5-year trough of $93.4 million in Q1 2021.
  • In the last 3 years, Arbutus Biopharma's Shares Outstanding (Diluted Average) had a median value of $185.6 million in 2024 and averaged $179.5 million.
  • Data for Arbutus Biopharma's Shares Outstanding (Diluted Average) shows a peak YoY surged of 58.86% (in 2022) over the last 5 years.
  • Arbutus Biopharma's Shares Outstanding (Diluted Average) (Quarterly) stood at $106.2 million in 2021, then soared by 42.07% to $150.9 million in 2022, then climbed by 9.95% to $166.0 million in 2023, then climbed by 11.84% to $185.6 million in 2024, then rose by 1.47% to $191.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $191.8 million for Q3 2025, versus $192.4 million for Q2 2025 and $190.7 million for Q1 2025.